Convalescent plasma from blood donors with anti-SARS-CoV-2 antibodies is a potential therapy for prevention and/or treatment of COVID-19. Since the beginning of the pandemic, there have been more than 100 clinical trials registered globally evaluating convalescent plasma or hyperimmune globulin for COVID-19. Considerations for evaluating convalescent plasma as a therapy include selection of patient populations most likely to benefit, blood donor eligibility and characteristics, optimal product characteristics and study design. Clinical trial results, including preliminary results from large, randomised controlled trials, have recently started to be reported. More data is required on the efficacy and safety of convalescent plasma early in the course of disease and in higher risk patient populations and on the optimal product characteristics.